{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T11:56:37Z","timestamp":1776167797594,"version":"3.50.1"},"reference-count":22,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pharmacy Research Committee from the Department of Pharmacy at Mayo Clinic"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>Itraconazole is the recommended first-line antifungal agent in blastomycosis treatment. However, pharmacokinetic limitations and adverse drug events may necessitate the use of alternative antifungal agents. The primary objective of the study was to retrospectively describe a cohort of patients with blastomycosis who received voriconazole (as partial or complete therapy), for complete or partial treatment, compared to those who received itraconazole alone. Secondary objectives included rationale for voriconazole selection, treatment response, mortality, and adverse drug events. This retrospective multicenter cohort study included adult patients with proven\/probable blastomycosis who received itraconazole or voriconazole. Treatment response was evaluated at one year or end of therapy, whichever came first. Mortality outcomes were assessed within 7 days of the last documented azole dose. Propensity score weighting and subgroup analysis were utilized to control confounding variables between cohorts. A total of 119 patients receiving itraconazole and 25 receiving voriconazole as complete or partial treatment were included. Voriconazole was often selected for CNS involvement or after intolerance to alternative azoles. After propensity score weighting, no significant difference in complete or partial treatment response was observed. Rates of all-cause mortality and blastomycosis-related mortality were numerically higher in the voriconazole cohort. Adverse drug event rates were similar between cohorts; however, discontinuation due to adverse events was more common in the voriconazole cohort. Voriconazole was most utilized for the treatment of blastomycosis in cases with CNS involvement or intolerance to other azoles. A statistically significant difference in response rate was not identified between voriconazole-containing or itraconazole-treated patients; however, given limited sample sizes, further data is needed to assess the equivalency of these agents in the treatment of blastomycosis.<\/jats:p>","DOI":"10.3390\/jof12040279","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T10:29:08Z","timestamp":1776162548000},"page":"279","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Retrospective, Comparative Cohort Analysis of the Utilization of Voriconazole-Containing Regimens Versus Itraconazole in the Treatment of Blastomycosis"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7889-4520","authenticated-orcid":false,"given":"Caitlin C.","family":"Schanz","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Boston Medical Center, Boston, MA 02118, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8308-3264","authenticated-orcid":false,"given":"Christina G.","family":"Rivera","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar M. Abu","family":"Saleh","sequence":"additional","affiliation":[{"name":"Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0400-0978","authenticated-orcid":false,"given":"Josh","family":"Clement","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, New York Presbyterian Hospital, New York, NY 10065, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J.","family":"Enzler","sequence":"additional","affiliation":[{"name":"Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6033-5142","authenticated-orcid":false,"given":"Danielle","family":"Firkus","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mayo Clinic Health System, Eau Claire, WI 54703, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8783-0191","authenticated-orcid":false,"given":"Kristin","family":"Cole","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6581-3956","authenticated-orcid":false,"given":"Paschalis","family":"Vergidis","sequence":"additional","affiliation":[{"name":"Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5050-6689","authenticated-orcid":false,"given":"Ryan W.","family":"Stevens","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Linder, K.A., Kauffman, C.A., and Miceli, M.H. (2023). Blastomycosis: A Review of Mycological and Clinical Aspects. J. Fungi, 9.","DOI":"10.3390\/jof9010117"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s11046-020-00431-2","article-title":"Re-drawing the Maps for Endemic Mycoses","volume":"185","author":"Ashraf","year":"2020","journal-title":"Mycopathologia"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11046-006-0018-9","article-title":"Geographic distribution of human blastomycosis cases in Milwaukee, Wisconsin, USA: Association with urban watersheds","volume":"161","author":"Baumgardner","year":"2006","journal-title":"Mycopathologia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1086\/588300","article-title":"Infectious Diseases Society of America Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America","volume":"46","author":"Chapman","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1016\/S1473-3099(21)00191-2","article-title":"Global guideline for the diagnosis and management of the endemic mycoses: An initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology","volume":"21","author":"Thompson","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/0002-9343(92)90575-V","article-title":"Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group","volume":"93","author":"Dismukes","year":"1992","journal-title":"Am. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.mayocpiqo.2020.05.006","article-title":"The Many Faces of Itraconazole Cardiac Toxicity","volume":"4","author":"Teaford","year":"2020","journal-title":"Mayo Clin. Proc. Innov. Qual. Outcomes"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1365-2710.2001.00338.x","article-title":"Itraconazole oral solution and intravenous formulations: A review of pharmacokinetics and pharmacodynamics","volume":"26","author":"Willems","year":"2001","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e0013421","DOI":"10.1128\/AAC.00134-21","article-title":"Bioavailability of Single-Dose SUBA-Itraconazole Compared to Conventional Itraconazole under Fasted and Fed Conditions","volume":"65","author":"Rauseo","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/myc.13565","article-title":"Does metabolite matter? Defining target itraconazole and hydroxy-itraconazole serum concentrations for blastomycosis","volume":"66","author":"Firkus","year":"2023","journal-title":"Mycoses"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/myc.13157","article-title":"Antifungal drugs: An updated review of central nervous system pharmacokinetics","volume":"63","author":"Wirth","year":"2020","journal-title":"Mycoses"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1128\/AAC.44.6.1734-1736.2000","article-title":"In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum","volume":"44","author":"Li","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/FPC.0000000000000277","article-title":"Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections","volume":"27","author":"Hamadeh","year":"2017","journal-title":"Pharmacogenet. Genomics"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e3727","DOI":"10.1093\/cid\/ciaa1555","article-title":"Voriconazole Versus Itraconazole for the Initial and Step-down Treatment of Histoplasmosis: A Retrospective Cohort","volume":"73","author":"Hendrix","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"26213","DOI":"10.1038\/srep26213","article-title":"Triazole resistance mediated by mutations of a conserved active site tyrosine in fungal lanosterol 14\u03b1-demethylase","volume":"6","author":"Sagatova","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1086\/650579","article-title":"Blastomycosis of the central nervous system: A multicenter review of diagnosis and treatment in the modern era","volume":"50","author":"Bariola","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1086\/429319","article-title":"Successful treatment of cerebral blastomycosis with voriconazole","volume":"40","author":"Bakleh","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1128\/AAC.01148-07","article-title":"Voriconazole use for endemic fungal infections","volume":"53","author":"Freifeld","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/13693780600803870","article-title":"Cerebral blastomycosis: A case series incorporating voriconazole in the treatment regimen","volume":"44","author":"Borgia","year":"2006","journal-title":"Med. Mycol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"ofac220","DOI":"10.1093\/ofid\/ofac220","article-title":"The role of isavuconazole sulphate for treatment of blastomycosis: A case series and antifungal susceptibility","volume":"9","author":"Scolarici","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Zhou, J., Wei, Z., Xu, B., Liu, M., Xu, R., and Wu, X. (2022). Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1039867"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1345\/aph.1H671","article-title":"Adverse effects of voriconazole: Analysis of the French Pharmacovigilance Database","volume":"41","author":"Eiden","year":"2007","journal-title":"Ann. Pharmacother."}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/12\/4\/279\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T11:07:30Z","timestamp":1776164850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/12\/4\/279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":22,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["jof12040279"],"URL":"https:\/\/doi.org\/10.3390\/jof12040279","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]}}}